On the Varieties of Conscious Experiences: Altered Beliefs Under Psychedelics (ALBUS)
This theory-building paper proposes the ALBUS (Altered Beliefs Under Psychedelics) model as an extension of the REBUS hypothesis, suggesting that 5-HT2A receptor activation can lead to both relaxation (REBUS) and strengthening (SEBUS) of beliefs depending on dosage and context. The authors draw parallels between psychedelic states and lucid dreaming, focusing on mechanisms of conscious perception, dreaming, and memory.
Authors
- Matthew Johnson
Published
Abstract
How is it that psychedelics so profoundly impact brain and mind? According to the model of Relaxed Beliefs Under Psychedelics (REBUS), 5-HT2a agonism is thought to help relax prior expectations, thus making room for new perspectives and patterns. Here, we introduce an alternative (but largely compatible) perspective, proposing that REBUS effects may primarily correspond to a particular (but potentially pivotal) regime of very high levels of 5-HT2a receptor agonism. Depending on both a variety of contextual factors and the specific neural systems being considered, we suggest opposite effects may also occur in which synchronous neural activity becomes more powerful, with accompanying Strengthened Beliefs Under Psychedelics (SEBUS) effects. Such SEBUS effects are consistent with the enhanced meaning-making observed in psychedelic therapy (e.g. psychological insight and the noetic quality of mystical experiences), with the imposition of prior expectations on perception (e.g. hallucinations and pareidolia), and with the delusional thinking that sometimes occurs during psychedelic experiences (e.g. apophenia, paranoia, engendering of inaccurate interpretations of events, and potentially false memories). With Altered Beliefs Under Psychedelics (ALBUS), we propose that the manifestation of SEBUS vs. REBUS effects may vary across the dose-response curve of 5-HT2a signaling. While we explore a diverse range of sometimes complex models, our basic idea is fundamentally simple: psychedelic experiences can be understood as kinds of waking dream states of varying degrees of lucidity, with similar underlying mechanisms. We further demonstrate the utility of ALBUS by providing neurophenomenological models of psychedelics focusing on mechanisms of conscious perceptual synthesis, dreaming, and episodic memory and mental simulation.
Research Summary of 'On the Varieties of Conscious Experiences: Altered Beliefs Under Psychedelics (ALBUS)'
Introduction
Earlier theorising about how classical psychedelics act on brain and mind has converged around predictive-processing accounts such as the Relaxed Beliefs Under Psychedelics (REBUS) model, which links 5-HT2a receptor agonism to a relaxation of high‑level priors and therefore greater influence of bottom‑up sensory evidence. At the same time, many phenomenological features of psychedelic experience—enhanced meaning, vivid imagery, pareidolia, hallucinations and sometimes delusional interpretations—are more naturally framed as cases in which prior expectations exert stronger influence over perception and cognition. Safron and colleagues situate these tensions within the broader “psychedelic renaissance” and argue that more nuanced, multiscale models are required if clinical translation and basic science are to proceed reliably. This paper introduces Altered Beliefs Under Psychedelics (ALBUS), a unifying conceptual framework that integrates REBUS with a complementary hypothesis termed Strengthened Beliefs Under Psychedelics (SEBUS). The authors propose that both relaxation and strengthening of beliefs can occur under 5-HT2a agonism depending on dose, neural subsystem, and contextual factors (including ‘‘set and setting’’), and they develop neurophenomenological and mechanistic models linking cortical microcircuits, oscillatory dynamics, hippocampal/entorhinal systems and modes of conscious perception to these opposing effects. ALBUS is presented as a hypothesis-generating synthesis that aims to explain a wide range of psychedelic phenomena—from waking dreaming and mystical noeticity to hallucinations and therapeutic insight—and to motivate specific empirical tests.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Topics
- Author
- APA Citation
Safron, A., Juliani, A., Reggente, N., Klimaj, V., & Johnson, M. (2025). On the Varieties of Conscious Experiences: Altered Beliefs Under Psychedelics (ALBUS). Neuroscience of Consciousness, 2025(1). https://doi.org/10.1093/nc/niae038
References (29)
Papers cited by this study that are also in Blossom
Amada, N., Shane, J. · Journal of Humanistic Psychology (2022)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)
Carhart-Harris, R. L., Friston, K. J. · Brain (2010)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)
Ciauncia, A., Safron, A. · Psyarxiv (2022)
Show all 29 referencesShow fewer
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)
Ekins, T. G., Brooks, I., Kailasa, S. et al. · Biorxiv (2023)
Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)
Erritzoe, D., Smith, J. M., Fisher, P. M. et al. · Journal of Psychopharmacology (2019)
Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)
Halberstadt, A. L., Chatha, M., Klein, A. K. et al. · Neuropharmacology (2020)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R. L. et al. · Schizophrenia Bulletin (2020)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
McGovern, H., Grimmer, H. J., Doss, M. K. et al. · Communications Psychology (2024)
Passie, T., Guss, J., Kraehenmann, R. · Frontiers in Psychiatry (2022)
Pink-Hashkes, S., Van Rooij, I., Kwisthout, J. · CogSci (2017)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)
Wießner, I., Falchi, M., Maia, L. O. et al. · Journal of Psychopharmacology (2022)
Cited By (6)
Papers in Blossom that reference this study
Stoliker, D., Preller, K. H., Novelli, L. et al. · Molecular Psychiatry (2024)
Sadibolova, R., Murray-Lawson, C., Family, N. et al. · Biorxiv (2023)
Aqil, M., Roseman, L. · Neuropharmacology (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Hipólito, I., Mago, J., Rosas, F. E. et al. · Psyarxiv (2022)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · MedRvix (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.